Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer

NCT01194960 is registered in ClinicalTrials.gov with Oxford BioMedica as lead sponsor.

NCT NCT01194960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01194960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer
Lead sponsor
Oxford BioMedica
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2010
Completion date
March 31, 2013
Enrollment
25 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hormone refractory prostate cancer